{"timeline":{"headline":"Neurobiology of Opioid Dependence: 2 - 2","type":"default","text":"History of NCT00000193","startDate":"2005,06,23","date": [{"startDate":"2005,06,23","headline":"View of NCT00000193 on 2005_06_23","text":"<table class=\"info\">\n<tr>\n<th nowrap=\"\">ClinicalTrials Identifier:</th><td>NCT00000193</td>\n</tr>\n<tr>\n<th>Updated:</th><td>2005_06_23</td>\n</tr>\n<tr>\n<th class=\"section\" colspan=\"2\">\n<h2>Descriptive Information</h2>\n</th>\n</tr>\n<tr>\n<th>Brief title</th><td>\n<p>Neurobiology of Opioid Dependence: 2 - 2</p>\n</td>\n</tr>\n<tr>\n<th>Official title</th><td>\n<p>Neurobiology of Opioid Dependence: 2</p>\n</td>\n</tr>\n<tr>\n<th>Brief summary</th>\n</tr>\n<tr>\n<td class=\"bigdent\" colspan=\"2\">\n<p>The purpose of this study is to evaluate the effects of gamma hydroxybutyric on naloxone-precipitated opiate withdrawal.</p>\n</td>\n</tr>\n<tr>\n<th>Detailed description</th>\n</tr>\n<tr>\n<td class=\"bigdent\" colspan=\"2\">\n<p></p>\n</td>\n</tr>\n<tr>\n<th>Phase</th><td>Phase 2</td>\n</tr>\n<tr>\n<th>Study type</th><td>Interventional</td>\n</tr>\n<tr>\n<th>Study design</th><td>Treatment</td>\n</tr>\n<tr>\n<th>Study design</th><td>Double Blind</td>\n</tr>\n<tr>\n<th>Study design</th><td>Placebo Control</td>\n</tr>\n<tr>\n<th>Primary outcome</th><td>Measure: \n         Behavioral, subjective, measures of naloxone-preci\n      </td>\n</tr>\n<tr>\n<th>Primary outcome</th><td>Measure: \n         Phsyiological, neuroendocrine measures of naloxone\n      </td>\n</tr>\n<tr>\n<th>Condition</th><td>\n         Opioid-Related Disorders\n      </td>\n</tr>\n<tr>\n<th>Intervention</th><td>\n<div>Drug: Gamma hydroxybutyric</div>\n</td>\n</tr>\n<tr>\n<th>Reference</th><td>\n<div>Citation: Neuropsychopharmacology, 1996; 14(3) pp 187-193. Neruopsychopharmacology 1996; 14(3), 187-193</div>\n<div>MEDLINE: </div>\n</td>\n</tr>\n<tr>\n<th class=\"section\" colspan=\"2\">\n<h2>Recruitment Information</h2>\n</th>\n</tr>\n<tr>\n<th>Status</th><td>\n            Completed\n         </td>\n</tr>\n<tr>\n<th>Start date</th><td>\n         1996-01\n      </td>\n</tr>\n<tr>\n<th>Last data entry date</th><td>\n         1996-10\n      </td>\n</tr>\n<tr>\n<th>Criteria</th>\n</tr>\n<tr>\n<td class=\"bigdent\" colspan=\"2\">\n<p>Please contact site for information.</p>\n</td>\n</tr>\n<tr>\n<th>Gender</th><td>\n            Male\n         </td>\n</tr>\n<tr>\n<th>Minimum age</th><td>N/A</td>\n</tr>\n<tr>\n<th>Maximum age</th><td>N/A</td>\n</tr>\n<tr>\n<th>Healthy volunteers</th><td>No</td>\n</tr>\n<tr>\n<th>Expected enrollment</th><td>0</td>\n</tr>\n<tr>\n<th class=\"section\" colspan=\"2\">\n<h2>Administrative Data</h2>\n</th>\n</tr>\n<tr>\n<th>Organization name</th><td>National Institute on Drug Abuse (NIDA)</td>\n</tr>\n<tr>\n<th>Organization study ID</th><td>NIDA-00191-2</td>\n</tr>\n<tr>\n<th>Secondary ID</th><td>\n            K20-00191-2\n         </td>\n</tr>\n<tr>\n<th>Sponsor</th><td>\n               National Institute on Drug Abuse (NIDA)\n            </td>\n</tr>\n<tr>\n<th>Collaborator</th><td>\n               Yale University\n            </td>\n</tr>\n<tr>\n<th>Health Authority</th><td>\n               United States: Federal Government\n         </td>\n</tr>\n</table>","asset":{"media":"","credit":"clinicaltrials.gov","caption":""}},{"startDate":"2005,06,30","headline":"View of NCT00000193 on 2005_06_30","text":"<body style=\"display:table; border-collapse:separate; border-spacing:10px;\"><div class=\"separation\" id=\"current\" style=\"display: table-cell; padding: 10px; border: 3px; border-style: solid; border-color: #bbbbbb;\"><table class=\"info\">\n<tr>\n<th nowrap=\"\">ClinicalTrials Identifier:</th><td>NCT00000193</td>\n</tr>\n<tr>\n<th>Updated:</th><td>2005_06_30</td>\n</tr>\n<tr>\n<th class=\"section\" colspan=\"2\">\n<h2>Descriptive Information</h2>\n</th>\n</tr>\n<tr>\n<th>Brief title</th><td>\n<p>Neurobiology of Opioid Dependence: 2 - 2</p>\n</td>\n</tr>\n<tr>\n<th>Official title</th><td>\n<p>Neurobiology of Opioid Dependence: 2</p>\n</td>\n</tr>\n<tr>\n<th>Brief summary</th>\n</tr>\n<tr>\n<td class=\"bigdent\" colspan=\"2\">\n<p>The purpose of this study is to evaluate the effects of gamma hydroxybutyric on naloxone-precipitated opiate withdrawal.</p>\n</td>\n</tr>\n<tr>\n<th>Detailed description</th>\n</tr>\n<tr>\n<td class=\"bigdent\" colspan=\"2\">\n<p></p>\n</td>\n</tr>\n<tr>\n<th>Phase</th><td>Phase 2</td>\n</tr>\n<tr>\n<th>Study type</th><td>Interventional</td>\n</tr>\n<tr>\n<th>Study design</th><td>Treatment</td>\n</tr>\n<tr>\n<th>Study design</th><td>Double Blind</td>\n</tr>\n<tr>\n<th>Study design</th><td>Placebo Control</td>\n</tr>\n<tr>\n<th>Primary outcome</th><td>Measure: \n         Behavioral, subjective, measures of naloxone-preci\n      </td>\n</tr>\n<tr>\n<th>Primary outcome</th><td>Measure: \n         Phsyiological, neuroendocrine measures of naloxone\n      </td>\n</tr>\n<tr>\n<th>Condition</th><td>\n         Opioid-Related Disorders\n      </td>\n</tr>\n<tr>\n<th>Intervention</th><td>\n<div>Drug: Gamma hydroxybutyric</div>\n</td>\n</tr>\n<tr>\n<th>Reference</th><td>\n<div>Citation: Neuropsychopharmacology, 1996; 14(3) pp 187-193. Neruopsychopharmacology 1996; 14(3), 187-193</div>\n<div>MEDLINE: </div>\n</td>\n</tr>\n<tr>\n<th class=\"section\" colspan=\"2\">\n<h2>Recruitment Information</h2>\n</th>\n</tr>\n<tr>\n<th>Status</th><td>\n            Completed\n         </td>\n</tr>\n<tr>\n<th>Start date</th><td>\n         1996-01\n      </td>\n</tr>\n<tr>\n<th>Last data entry date</th><td>\n         1996-10\n      </td>\n</tr>\n<tr>\n<th>Criteria</th>\n</tr>\n<tr>\n<td class=\"bigdent\" colspan=\"2\">\n<p>Please contact site for information.</p>\n</td>\n</tr>\n<tr>\n<th>Gender</th><td>\n            Male\n         </td>\n</tr>\n<tr>\n<th>Minimum age</th><td>N/A</td>\n</tr>\n<tr>\n<th>Maximum age</th><td>N/A</td>\n</tr>\n<tr>\n<th>Healthy volunteers</th><td>No</td>\n</tr>\n<tr>\n<th>Expected enrollment</th><td>0</td>\n</tr>\n<tr>\n<th class=\"section\" colspan=\"2\">\n<h2>Administrative Data</h2>\n</th>\n</tr>\n<tr>\n<th>Organization name</th><td>National Institute on Drug Abuse (NIDA)</td>\n</tr>\n<tr>\n<th>Organization study ID</th><td>NIDA-00191-2</td>\n</tr>\n<tr>\n<th>Secondary ID</th><td>\n            K20-00191-2\n         </td>\n</tr>\n<tr>\n<th>Sponsor</th><td>\n               National Institute on Drug Abuse (NIDA)\n            </td>\n</tr>\n<tr>\n<th>Collaborator</th><td>\n               Yale University\n            </td>\n</tr>\n<tr>\n<th>Health Authority</th><td>\n               United States: Federal Government\n         </td>\n</tr>\n</table></div><div class=\"separation\" id=\"past\" style=\"display: table-cell; padding: 10px; border: 3px; border-style: solid; border-color: #bbbbbb;\"><html><body><span>&lt;table class=\"info\"&gt;<br/>&lt;tr&gt;<br/>&lt;th nowrap=\"\"&gt;ClinicalTrials Identifier:&lt;/th&gt;&lt;td&gt;NCT00000193&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Updated:&lt;/th&gt;&lt;td&gt;2005_06_</span><del style=\"background:#ffe6e6;\">2</del><span>3</span><ins style=\"background:#e6ffe6;\">0</ins><span>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th class=\"section\" colspan=\"2\"&gt;<br/>&lt;h2&gt;Descriptive Information&lt;/h2&gt;<br/>&lt;/th&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Brief title&lt;/th&gt;&lt;td&gt;<br/>&lt;p&gt;Neurobiology of Opioid Dependence: 2 - 2&lt;/p&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Official title&lt;/th&gt;&lt;td&gt;<br/>&lt;p&gt;Neurobiology of Opioid Dependence: 2&lt;/p&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Brief summary&lt;/th&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;td class=\"bigdent\" colspan=\"2\"&gt;<br/>&lt;p&gt;The purpose of this study is to evaluate the effects of gamma hydroxybutyric on naloxone-precipitated opiate withdrawal.&lt;/p&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Detailed description&lt;/th&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;td class=\"bigdent\" colspan=\"2\"&gt;<br/>&lt;p&gt;&lt;/p&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Phase&lt;/th&gt;&lt;td&gt;Phase 2&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Study type&lt;/th&gt;&lt;td&gt;Interventional&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Study design&lt;/th&gt;&lt;td&gt;Treatment&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Study design&lt;/th&gt;&lt;td&gt;Double Blind&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Study design&lt;/th&gt;&lt;td&gt;Placebo Control&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Primary outcome&lt;/th&gt;&lt;td&gt;Measure: <br/>         Behavioral, subjective, measures of naloxone-preci<br/>      &lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Primary outcome&lt;/th&gt;&lt;td&gt;Measure: <br/>         Phsyiological, neuroendocrine measures of naloxone<br/>      &lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Condition&lt;/th&gt;&lt;td&gt;<br/>         Opioid-Related Disorders<br/>      &lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Intervention&lt;/th&gt;&lt;td&gt;<br/>&lt;div&gt;Drug: Gamma hydroxybutyric&lt;/div&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Reference&lt;/th&gt;&lt;td&gt;<br/>&lt;div&gt;Citation: Neuropsychopharmacology, 1996; 14(3) pp 187-193. Neruopsychopharmacology 1996; 14(3), 187-193&lt;/div&gt;<br/>&lt;div&gt;MEDLINE: &lt;/div&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th class=\"section\" colspan=\"2\"&gt;<br/>&lt;h2&gt;Recruitment Information&lt;/h2&gt;<br/>&lt;/th&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Status&lt;/th&gt;&lt;td&gt;<br/>            Completed<br/>         &lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Start date&lt;/th&gt;&lt;td&gt;<br/>         1996-01<br/>      &lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Last data entry date&lt;/th&gt;&lt;td&gt;<br/>         1996-10<br/>      &lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Criteria&lt;/th&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;td class=\"bigdent\" colspan=\"2\"&gt;<br/>&lt;p&gt;Please contact site for information.&lt;/p&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Gender&lt;/th&gt;&lt;td&gt;<br/>            Male<br/>         &lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Minimum age&lt;/th&gt;&lt;td&gt;N/A&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Maximum age&lt;/th&gt;&lt;td&gt;N/A&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Healthy volunteers&lt;/th&gt;&lt;td&gt;No&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Expected enrollment&lt;/th&gt;&lt;td&gt;0&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th class=\"section\" colspan=\"2\"&gt;<br/>&lt;h2&gt;Administrative Data&lt;/h2&gt;<br/>&lt;/th&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Organization name&lt;/th&gt;&lt;td&gt;National Institute on Drug Abuse (NIDA)&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Organization study ID&lt;/th&gt;&lt;td&gt;NIDA-00191-2&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Secondary ID&lt;/th&gt;&lt;td&gt;<br/>            K20-00191-2<br/>         &lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Sponsor&lt;/th&gt;&lt;td&gt;<br/>               National Institute on Drug Abuse (NIDA)<br/>            &lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Collaborator&lt;/th&gt;&lt;td&gt;<br/>               Yale University<br/>            &lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Health Authority&lt;/th&gt;&lt;td&gt;<br/>               United States: Federal Government<br/>         &lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;/table&gt;</span></body></html></div></body>","asset":{"media":"","credit":"clinicaltrials.gov","caption":""}},{"startDate":"2005,12,08","headline":"View of NCT00000193 on 2005_12_08","text":"<body style=\"display:table; border-collapse:separate; border-spacing:10px;\"><div class=\"separation\" id=\"current\" style=\"display: table-cell; padding: 10px; border: 3px; border-style: solid; border-color: #bbbbbb;\"><table class=\"info\">\n<tr>\n<th nowrap=\"\">ClinicalTrials Identifier:</th><td>NCT00000193</td>\n</tr>\n<tr>\n<th>Updated:</th><td>2005_12_08</td>\n</tr>\n<tr>\n<th class=\"section\" colspan=\"2\">\n<h2>Descriptive Information</h2>\n</th>\n</tr>\n<tr>\n<th>Brief title</th><td>\n<p>Neurobiology of Opioid Dependence: 2 - 2</p>\n</td>\n</tr>\n<tr>\n<th>Official title</th><td>\n<p>Neurobiology of Opioid Dependence: 2</p>\n</td>\n</tr>\n<tr>\n<th>Brief summary</th>\n</tr>\n<tr>\n<td class=\"bigdent\" colspan=\"2\">\n<p>The purpose of this study is to evaluate the effects of gamma hydroxybutyric on naloxone-precipitated opiate withdrawal.</p>\n</td>\n</tr>\n<tr>\n<th>Detailed description</th>\n</tr>\n<tr>\n<td class=\"bigdent\" colspan=\"2\">\n<p></p>\n</td>\n</tr>\n<tr>\n<th>Phase</th><td>Phase 2</td>\n</tr>\n<tr>\n<th>Study type</th><td>Interventional</td>\n</tr>\n<tr>\n<th>Study design</th><td>Treatment</td>\n</tr>\n<tr>\n<th>Study design</th><td>Double Blind</td>\n</tr>\n<tr>\n<th>Study design</th><td>Placebo Control</td>\n</tr>\n<tr>\n<th>Primary outcome</th><td>Measure: \n         Behavioral, subjective, measures of naloxone-preci\n      </td>\n</tr>\n<tr>\n<th>Primary outcome</th><td>Measure: \n         Phsyiological, neuroendocrine measures of naloxone\n      </td>\n</tr>\n<tr>\n<th>Condition</th><td>\n         Opioid-Related Disorders\n      </td>\n</tr>\n<tr>\n<th>Intervention</th><td>\n<div>Drug: Gamma hydroxybutyric</div>\n</td>\n</tr>\n<tr>\n<th>Reference</th><td>\n<div>Citation: Neuropsychopharmacology, 1996; 14(3) pp 187-193. Neruopsychopharmacology 1996; 14(3), 187-193</div>\n<div>MEDLINE: </div>\n</td>\n</tr>\n<tr>\n<th class=\"section\" colspan=\"2\">\n<h2>Recruitment Information</h2>\n</th>\n</tr>\n<tr>\n<th>Status</th><td>\n            Completed\n         </td>\n</tr>\n<tr>\n<th>Start date</th><td>\n         1996-01\n      </td>\n</tr>\n<tr>\n<th>Last data entry date</th><td>\n         1996-10\n      </td>\n</tr>\n<tr>\n<th>Criteria</th>\n</tr>\n<tr>\n<td class=\"bigdent\" colspan=\"2\">\n<p>Please contact site for information.</p>\n</td>\n</tr>\n<tr>\n<th>Gender</th><td>\n            Male\n         </td>\n</tr>\n<tr>\n<th>Minimum age</th><td>N/A</td>\n</tr>\n<tr>\n<th>Maximum age</th><td>N/A</td>\n</tr>\n<tr>\n<th>Healthy volunteers</th><td>No</td>\n</tr>\n<tr>\n<th>Expected enrollment</th><td>0</td>\n</tr>\n<tr>\n<th class=\"section\" colspan=\"2\">\n<h2>Administrative Data</h2>\n</th>\n</tr>\n<tr>\n<th>Organization name</th><td>National Institute on Drug Abuse (NIDA)</td>\n</tr>\n<tr>\n<th>Organization study ID</th><td>NIDA-00191-2</td>\n</tr>\n<tr>\n<th>Secondary ID</th><td>\n            K20-00191-2\n         </td>\n</tr>\n<tr>\n<th>Sponsor</th><td>\n               National Institute on Drug Abuse (NIDA)\n            </td>\n</tr>\n<tr>\n<th>Collaborator</th><td>\n               Yale University\n            </td>\n</tr>\n<tr>\n<th>Health Authority</th><td>\n               United States: Federal Government\n         </td>\n</tr>\n</table></div><div class=\"separation\" id=\"past\" style=\"display: table-cell; padding: 10px; border: 3px; border-style: solid; border-color: #bbbbbb;\"><html><body><span>&lt;table class=\"info\"&gt;<br/>&lt;tr&gt;<br/>&lt;th nowrap=\"\"&gt;ClinicalTrials Identifier:&lt;/th&gt;&lt;td&gt;NCT00000193&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Updated:&lt;/th&gt;&lt;td&gt;2005_</span><del style=\"background:#ffe6e6;\">06_30</del><ins style=\"background:#e6ffe6;\">12_08</ins><span>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th class=\"section\" colspan=\"2\"&gt;<br/>&lt;h2&gt;Descriptive Information&lt;/h2&gt;<br/>&lt;/th&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Brief title&lt;/th&gt;&lt;td&gt;<br/>&lt;p&gt;Neurobiology of Opioid Dependence: 2 - 2&lt;/p&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Official title&lt;/th&gt;&lt;td&gt;<br/>&lt;p&gt;Neurobiology of Opioid Dependence: 2&lt;/p&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Brief summary&lt;/th&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;td class=\"bigdent\" colspan=\"2\"&gt;<br/>&lt;p&gt;The purpose of this study is to evaluate the effects of gamma hydroxybutyric on naloxone-precipitated opiate withdrawal.&lt;/p&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Detailed description&lt;/th&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;td class=\"bigdent\" colspan=\"2\"&gt;<br/>&lt;p&gt;&lt;/p&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Phase&lt;/th&gt;&lt;td&gt;Phase 2&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Study type&lt;/th&gt;&lt;td&gt;Interventional&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Study design&lt;/th&gt;&lt;td&gt;Treatment&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Study design&lt;/th&gt;&lt;td&gt;Double Blind&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Study design&lt;/th&gt;&lt;td&gt;Placebo Control&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Primary outcome&lt;/th&gt;&lt;td&gt;Measure: <br/>         Behavioral, subjective, measures of naloxone-preci<br/>      &lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Primary outcome&lt;/th&gt;&lt;td&gt;Measure: <br/>         Phsyiological, neuroendocrine measures of naloxone<br/>      &lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Condition&lt;/th&gt;&lt;td&gt;<br/>         Opioid-Related Disorders<br/>      &lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Intervention&lt;/th&gt;&lt;td&gt;<br/>&lt;div&gt;Drug: Gamma hydroxybutyric&lt;/div&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Reference&lt;/th&gt;&lt;td&gt;<br/>&lt;div&gt;Citation: Neuropsychopharmacology, 1996; 14(3) pp 187-193. Neruopsychopharmacology 1996; 14(3), 187-193&lt;/div&gt;<br/>&lt;div&gt;MEDLINE: &lt;/div&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th class=\"section\" colspan=\"2\"&gt;<br/>&lt;h2&gt;Recruitment Information&lt;/h2&gt;<br/>&lt;/th&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Status&lt;/th&gt;&lt;td&gt;<br/>            Completed<br/>         &lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Start date&lt;/th&gt;&lt;td&gt;<br/>         1996-01<br/>      &lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Last data entry date&lt;/th&gt;&lt;td&gt;<br/>         1996-10<br/>      &lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Criteria&lt;/th&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;td class=\"bigdent\" colspan=\"2\"&gt;<br/>&lt;p&gt;Please contact site for information.&lt;/p&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Gender&lt;/th&gt;&lt;td&gt;<br/>            Male<br/>         &lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Minimum age&lt;/th&gt;&lt;td&gt;N/A&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Maximum age&lt;/th&gt;&lt;td&gt;N/A&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Healthy volunteers&lt;/th&gt;&lt;td&gt;No&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Expected enrollment&lt;/th&gt;&lt;td&gt;0&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th class=\"section\" colspan=\"2\"&gt;<br/>&lt;h2&gt;Administrative Data&lt;/h2&gt;<br/>&lt;/th&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Organization name&lt;/th&gt;&lt;td&gt;National Institute on Drug Abuse (NIDA)&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Organization study ID&lt;/th&gt;&lt;td&gt;NIDA-00191-2&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Secondary ID&lt;/th&gt;&lt;td&gt;<br/>            K20-00191-2<br/>         &lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Sponsor&lt;/th&gt;&lt;td&gt;<br/>               National Institute on Drug Abuse (NIDA)<br/>            &lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Collaborator&lt;/th&gt;&lt;td&gt;<br/>               Yale University<br/>            &lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Health Authority&lt;/th&gt;&lt;td&gt;<br/>               United States: Federal Government<br/>         &lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;/table&gt;</span></body></html></div></body>","asset":{"media":"","credit":"clinicaltrials.gov","caption":""}},{"startDate":"2013,09,26","headline":"View of NCT00000193 on 2013_09_26","text":"<body style=\"display:table; border-collapse:separate; border-spacing:10px;\"><div class=\"separation\" id=\"current\" style=\"display: table-cell; padding: 10px; border: 3px; border-style: solid; border-color: #bbbbbb;\"><table class=\"info\">\n<tr>\n<th nowrap=\"\">ClinicalTrials Identifier:</th><td>NCT00000193</td>\n</tr>\n<tr>\n<th>Updated:</th><td>2013_09_26</td>\n</tr>\n<tr>\n<th class=\"section\" colspan=\"2\">\n<h2>Descriptive Information</h2>\n</th>\n</tr>\n<tr>\n<th>Brief title</th><td>\n<p>Neurobiology of Opioid Dependence: 2 - 2</p>\n</td>\n</tr>\n<tr>\n<th>Official title</th><td>\n<p>Neurobiology of Opioid Dependence: 2</p>\n</td>\n</tr>\n<tr>\n<th>Brief summary</th>\n</tr>\n<tr>\n<td class=\"bigdent\" colspan=\"2\">\n<p>The purpose of this study is to evaluate the effects of gamma hydroxybutyric on naloxone-precipitated opiate withdrawal.</p>\n</td>\n</tr>\n<tr>\n<th>Detailed description</th>\n</tr>\n<tr>\n<td class=\"bigdent\" colspan=\"2\">\n<p></p>\n</td>\n</tr>\n<tr>\n<th>Phase</th><td>Phase 2</td>\n</tr>\n<tr>\n<th>Study type</th><td>Interventional</td>\n</tr>\n<tr>\n<th>Study design</th><td>Treatment</td>\n</tr>\n<tr>\n<th>Study design</th><td>Double Blind</td>\n</tr>\n<tr>\n<th>Primary outcome</th><td>Measure: Behavioral, subjective, measures of naloxone-preci</td>\n</tr>\n<tr>\n<th>Primary outcome</th><td>Measure: Phsyiological, neuroendocrine measures of naloxone</td>\n</tr>\n<tr>\n<th>Condition</th><td>\n         Opioid-Related Disorders\n      </td>\n</tr>\n<tr>\n<th>Intervention</th><td>\n<div>Drug: Gamma hydroxybutyric</div>\n<p></p>\n</td>\n</tr>\n<tr>\n<th>Reference</th><td>\n<div>Citation: Neuropsychopharmacology, 1996; 14(3) pp 187-193. Neruopsychopharmacology 1996; 14(3), 187-193</div>\n<div>MEDLINE: </div>\n</td>\n</tr>\n<tr>\n<th class=\"section\" colspan=\"2\">\n<h2>Recruitment Information</h2>\n</th>\n</tr>\n<tr>\n<th>Status</th><td>Withdrawn</td>\n</tr>\n<tr>\n<th>Start date</th><td>\n         1993-01\n      </td>\n</tr>\n<tr>\n<th>Last follow-up date</th><td>\n         1998-01\n      \n      (Actual)\n  </td>\n</tr>\n<tr>\n<th>Primary completion date</th><td>\n         1998-01\n      \n      (Actual)\n  </td>\n</tr>\n<tr>\n<th>Criteria</th>\n</tr>\n<tr>\n<td class=\"bigdent\" colspan=\"2\">\n<p>Please contact site for information.</p>\n</td>\n</tr>\n<tr>\n<th>Gender</th><td>\n            Male\n         </td>\n</tr>\n<tr>\n<th>Healthy volunteers</th><td>No</td>\n</tr>\n<tr>\n<th class=\"section\" colspan=\"2\">\n<h2>Administrative Data</h2>\n</th>\n</tr>\n<tr>\n<th>Organization name</th><td>Yale University</td>\n</tr>\n<tr>\n<th>Organization study ID</th><td>NIDA-00191-2</td>\n</tr>\n<tr>\n<th>Secondary ID</th><td>K20DA000191\n      (US NIH Grant Number)\n    </td>\n</tr>\n<tr>\n<th>Secondary ID</th><td>\n            K20-00191-2\n         </td>\n</tr>\n<tr>\n<th>Sponsor</th><td>\n               Yale University\n            </td>\n</tr>\n<tr>\n<th>Collaborator</th><td>\n               National Institute on Drug Abuse (NIDA)\n            </td>\n</tr>\n<tr>\n<th>Collaborator</th><td>\n               Yale University\n            </td>\n</tr>\n<tr>\n<th>Health Authority</th><td>\n               United States: Federal Government\n         </td>\n</tr>\n</table></div><div class=\"separation\" id=\"past\" style=\"display: table-cell; padding: 10px; border: 3px; border-style: solid; border-color: #bbbbbb;\"><html><body><span>&lt;table class=\"info\"&gt;<br/>&lt;tr&gt;<br/>&lt;th nowrap=\"\"&gt;ClinicalTrials Identifier:&lt;/th&gt;&lt;td&gt;NCT00000193&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Updated:&lt;/th&gt;&lt;td&gt;20</span><del style=\"background:#ffe6e6;\">05_12_08</del><ins style=\"background:#e6ffe6;\">13_09_26</ins><span>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th class=\"section\" colspan=\"2\"&gt;<br/>&lt;h2&gt;Descriptive Information&lt;/h2&gt;<br/>&lt;/th&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Brief title&lt;/th&gt;&lt;td&gt;<br/>&lt;p&gt;Neurobiology of Opioid Dependence: 2 - 2&lt;/p&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Official title&lt;/th&gt;&lt;td&gt;<br/>&lt;p&gt;Neurobiology of Opioid Dependence: 2&lt;/p&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Brief summary&lt;/th&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;td class=\"bigdent\" colspan=\"2\"&gt;<br/>&lt;p&gt;The purpose of this study is to evaluate the effects of gamma hydroxybutyric on naloxone-precipitated opiate withdrawal.&lt;/p&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Detailed description&lt;/th&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;td class=\"bigdent\" colspan=\"2\"&gt;<br/>&lt;p&gt;&lt;/p&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Phase&lt;/th&gt;&lt;td&gt;Phase 2&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Study type&lt;/th&gt;&lt;td&gt;Interventional&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Study design&lt;/th&gt;&lt;td&gt;Treatment&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Study design&lt;/th&gt;&lt;td&gt;Double Blind&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/></span><del style=\"background:#ffe6e6;\">&lt;th&gt;Study design&lt;/th&gt;&lt;td&gt;Placebo Control&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/></del><span>&lt;th&gt;Primary outcome&lt;/th&gt;&lt;td&gt;Measure: </span><del style=\"background:#ffe6e6;\"><br/> </del><span>Behavioral, subjective, measures of naloxone-preci</span><del style=\"background:#ffe6e6;\"><br/> </del><span>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Primary outcome&lt;/th&gt;&lt;td&gt;Measure: </span><del style=\"background:#ffe6e6;\"><br/> </del><span>Phsyiological, neuroendocrine measures of naloxone</span><del style=\"background:#ffe6e6;\"><br/> </del><span>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Condition&lt;/th&gt;&lt;td&gt;<br/>         Opioid-Related Disorders<br/>      &lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Intervention&lt;/th&gt;&lt;td&gt;<br/>&lt;div&gt;Drug: Gamma hydroxybutyric&lt;/div&gt;<br/></span><ins style=\"background:#e6ffe6;\">&lt;p&gt;&lt;/p&gt;<br/></ins><span>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Reference&lt;/th&gt;&lt;td&gt;<br/>&lt;div&gt;Citation: Neuropsychopharmacology, 1996; 14(3) pp 187-193. Neruopsychopharmacology 1996; 14(3), 187-193&lt;/div&gt;<br/>&lt;div&gt;MEDLINE: &lt;/div&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th class=\"section\" colspan=\"2\"&gt;<br/>&lt;h2&gt;Recruitment Information&lt;/h2&gt;<br/>&lt;/th&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Status&lt;/th&gt;&lt;td&gt;</span><del style=\"background:#ffe6e6;\"><br/>            Completed<br/> </del><ins style=\"background:#e6ffe6;\">Withdrawn</ins><span>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Start date&lt;/th&gt;&lt;td&gt;<br/>         199</span><del style=\"background:#ffe6e6;\">6</del><ins style=\"background:#e6ffe6;\">3</ins><span>-01<br/>      &lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Last </span><del style=\"background:#ffe6e6;\">data entry</del><ins style=\"background:#e6ffe6;\">follow-up date&lt;/th&gt;&lt;td&gt;<br/>         1998-01<br/> <br/>      (Actual)<br/>  &lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Primary completion</ins><span> date&lt;/th&gt;&lt;td&gt;<br/>         199</span><del style=\"background:#ffe6e6;\">6-10</del><ins style=\"background:#e6ffe6;\">8-01</ins><span><br/> </span><ins style=\"background:#e6ffe6;\"><br/>      (Actual)<br/> </ins><span>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Criteria&lt;/th&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;td class=\"bigdent\" colspan=\"2\"&gt;<br/>&lt;p&gt;Please contact site for information.&lt;/p&gt;<br/>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Gender&lt;/th&gt;&lt;td&gt;<br/>            Male<br/>         &lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;</span><del style=\"background:#ffe6e6;\">Minimum age&lt;/th&gt;&lt;td&gt;N/A&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Maximum age&lt;/th&gt;&lt;td&gt;N/A&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Healthy volunteers&lt;/th&gt;&lt;td&gt;No&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Expected enrollment&lt;/th&gt;&lt;td&gt;0</del><ins style=\"background:#e6ffe6;\">Healthy volunteers&lt;/th&gt;&lt;td&gt;No</ins><span>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th class=\"section\" colspan=\"2\"&gt;<br/>&lt;h2&gt;Administrative Data&lt;/h2&gt;<br/>&lt;/th&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Organization name&lt;/th&gt;&lt;td&gt;</span><del style=\"background:#ffe6e6;\">National Institute on Drug Abuse (NIDA)</del><ins style=\"background:#e6ffe6;\">Yale University</ins><span>&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Organization study ID&lt;/th&gt;&lt;td&gt;NIDA-00191-2&lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Secondary ID&lt;/th&gt;&lt;td&gt;</span><ins style=\"background:#e6ffe6;\">K20DA000191<br/>      (US NIH Grant Number)<br/>    &lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Secondary ID&lt;/th&gt;&lt;td&gt;</ins><span><br/></span><del style=\"background:#ffe6e6;\"> </del><span> </span><ins style=\"background:#e6ffe6;\"> </ins><span>K20-00191-2<br/>         &lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Sponsor&lt;/th&gt;&lt;td&gt;<br/></span><ins style=\"background:#e6ffe6;\">               Yale University<br/>            &lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Collaborator&lt;/th&gt;&lt;td&gt;<br/></ins><span>               National Institute on Drug Abuse (NIDA)<br/>            &lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Collaborator&lt;/th&gt;&lt;td&gt;<br/>               Yale University<br/>            &lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;tr&gt;<br/>&lt;th&gt;Health Authority&lt;/th&gt;&lt;td&gt;<br/>               United States: Federal Government<br/>         &lt;/td&gt;<br/>&lt;/tr&gt;<br/>&lt;/table&gt;</span></body></html></div></body>","asset":{"media":"","credit":"clinicaltrials.gov","caption":""}}]}}